Loading...
Loading...
ATHA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 21.2M |
| Operating I/L | -24.1M |
| Other Income/Expense | 3.9M |
| Interest Income | 1.0M |
| Pretax | -20.2M |
| Income Tax Expense | -3.9M |
| Net Income/Loss | -16.2M |
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company specializing in the development of small molecules to address neurodegenerative diseases. Its lead product candidate, ATH-1017, is undergoing Phase 3 and Phase 2 clinical trials for Alzheimer's and Parkinson's diseases, respectively. The company also has preclinical stage product candidates, including ATH-1019 for peripheral nervous system indications and ATH-1020 for neuropsychiatric conditions.
